SQUAWK/NEWS
Menu
Live News EQUITY M impact

Viridian Therapeutics Terminates Agreement

Viridian Therapeutics ends material definitive agreement, details in 8-K filing. Potential impact on company operations.

VRDN

Filed: 2026-05-28 AccNo: 0001193125-26-245186 Size: 149 KB Item 1.02: Termination of a Material Definitive Agreement